Fortrea Holdings Inc. (FTRE)vsEli Lilly and Company (LLY)
FTRE
Fortrea Holdings Inc.
$17.20
+1.06%
HEALTHCARE · Cap: $1.60B
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2876% more annual revenue ($79.67B vs $2.68B). LLY leads profitability with a 33.5% profit margin vs -3.2%. FTRE appears more attractively valued with a PEG of 0.34. LLY earns a higher WallStSmart Score of 76/100 (B+).
FTRE
Hold40
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.2%
Fair Value
$8.21
Current Price
$17.20
$8.99 premium
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : FTRE
The primary concerns for FTRE are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
FTRE profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
FTRE carries more volatility with a beta of 1.95 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 40/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?